4.74k followers • 19 symbols Watchlist by Motif Investing
Successful drug approvals by the FDA and innovations in the treatment of cancer could provide relevant stocks a boost.
The largest Insider Buys this week were for Union Pacific Corp. (UNP), 3M Co. (MMM), Bristol-Myers Squibb Company (BMY) and Ford Motor Co. (NYSE:F). Director William J. Delaney III bought 5,000 shares of UNP stock on May 20 at the average price of $174.06. Warning! GuruFocus has detected 7 Warning Signs with UA.
Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bristol-Myers (BMY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Key highlights of the week include Merck's (MRK) offer to buy private cancer biotech and AbbVie (ABBV) and Lilly's (LLY) updates from clinical studies.
We highlight three stocks that are using innovative ways to treat cancer, also called malignancy. These stocks are also great long-term investments.
Synlogic (SYBX) announces clinical collaboration with Roche to develop its pre-clinical cancer candidate in combination with Roche's PD-L1 inhibitor, Tecentriq.
Novartis (NVS) reports encouraging data on combination asthma drug. The company also highlights its growth plans at its annual meet.
Exact Sciences Corporation's (NASDAQ:EXAS): Exact Sciences Corporation, a molecular diagnostics company, focuses on...
These companies could make a big difference in how the disease is diagnosed and treated. And their stocks could make a big difference for long-term investors.
Cannabis company Canopy Growth (NYSE:CGC) may have just secured its highest-profile celebrity endorsement yet. Perhaps only topped by the well-publicized relationship between Oprah Winfrey and Weight Watchers (NASDAQ:WW), lifestyle icon Martha Stewart just revealed she invested in an undisclosed stake in Canopy Growth stock because cannabis and cannabinol products are an "alternative to opioids."Source: Shutterstock She's probably not wrong. Insys Therapeutics (NASDAQ:INSY) and Cara Therapeutics (NASDAQ:CARA) are just a couple of several pharmaceutical companies developing ways to use the unique properties of the plant to make effective but not addictive pain-killers.Still, some industry experts are skeptical, and even if the CBD is the basis for an alternative to opioids the world hopes it will be, Canopy Growth role in that sliver of the cannabis movement is modest, at best. Its rise to prominence has been almost entirely driven by recreational use.InvestorPlace - Stock Market News, Stock Advice & Trading TipsTake a closer look at the company though, and you'll find a handful of the (too many) different entities Canopy Growth owns are actually taking aim at the opioid epidemic. * 7 Safe Stocks to Buy for Anxious Investors Pain Relief and Canopy Growth StockThe 77-year Stewart is as in-touch with societal trends as any millennial is, recently explaining of her investment in Canopy Growth stock to Create & Cultivate's founder Jaclyn Johnson, "Well, it's the modern thing, and it's an alternative to opioids of course."It is indeed the modern thing to do. More than 60% of Americans now favor legalizing marijuana, and cannabis has promise as a strong pain reliever.The former model and TV show host went on to undermine her case, however, adding, "I have a lot of animals, and I would love to be able to relieve stress or arthritis or other kinds of problems that my horses, my dogs, my cats experience. We're working on that first, and we're working on additions to human food stuffs, and also on cosmetics."To-date, recreational marijuana has been the crux of the story surrounding Canopy Growth. Of its fiscal Q3 sales of 10,102 kilograms, up 334% year-over-year, the vast majority of it was for recreational usage.The company isn't ignoring its potential role as a supplier of cannabis for true medicinal purposes though. Pharma and Canopy Growth StockAs of the latest look, Canopy owns eight diverse brands, including the relatively new Spectrum Therapeutics, which serves as "the company's healthcare professional and patient-facing identity in medical markets in Canada and around the world." While new, the division has still been undersold.Spectrum Therapeutics is a three-branch unit. Canadian consumers are likely most familiar with Spectrum Cannabis, which supplies medical cannabis using a clever-though-not-complicated color-coding system.It's the other two divisions of Spectrum, however, that quietly look and feel more like pharma companies than a means of simply scoring a high.Canopy Health Innovations, for instance, has secured 38 provisional patents in the United States with more on the way. Overseas, it's involved in eleven different drug-development trials.Cannabinoid Compound Company, also referred to as C3, is Europe's largest cannabinoid-based pharmaceuticals company. Granted, that doesn't necessarily mean a whole lot just yet. The company's dronabinol, however, can be "prescribed by doctors in Germany for any type of chronic pain, and for any condition in palliative care."It's a credible start towards becoming the opioid alternative Martha Stewart believes is possible.Adding to that credibility is the fact that the NFL is exploring the use of cannabis as a means of treating players' pains. That follows a partnership forged between the NHL Alumni Association and Canopy Growth earlier this year, to explore cannabinoids as a means of treating post-concussion neurological diseases… an area the NFL should be exploring as well. Looking Ahead for Canopy Growth StockDon't misread the message. An investment in Canopy Growth stock is an investment in many things, but an investment in opioid alternatives is the least of them. And, it could take years for the prescription-based use of cannabis to catch up with Canopy's recreational business. If that's the impact Stewart is betting on, it could be a long and rocky wait.It's still on the radar though. And, with the opioid market expected to be worth roughly $35 billion by 2025, it's a prospect that would certainly make for a solid second-act from the company. Or, maybe a third act, if the United States legalizes marijuana at the federal level. While certainly game-changing, recreational usage can't drive double-digit and triple-digit growth forever.Besides, the bigger the recreational market gets, the more competitive it becomes, and we've already seen the prices of marijuana fall as it becomes increasingly commoditized.Prescription-based products, preferably co-developed with a major partner, could prove to be a key means for Canopy Growth to differentiate itself and establish a longer-lasting, better-defended growth engine. You've just heard very little about the potential opportunity because it's such a long-term one.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Safe Stocks to Buy for Anxious Investors * 4 Tech Stocks Looking Vulnerable * Should You Buy, Sell, Or Hold These 7 Hot IPO Stocks? Compare Brokers The post Even with a Pharma Arm, Canopy Growth Stock Is About Recreational Use appeared first on InvestorPlace.
Array BioPharma's (ARRY) phase III study, evaluating the Braftovi triplet for treating metastatic colorectal cancer, meets the primary goal of ORR and OS. Shares rally.
Mallinckrodt (MNK) declines after filing suit against HHS and CMS for the protection of Medicaid patient access to Acthar.
Two big pharma titans are battling for supremacy in the field of oncology immunotherapy. From the looks of it, Kenilworth, New Jersey-based Merck & Co., Inc. (NYSE: MRK) may have the upper hand over Bristol-Myers Squibb Co (NYSE: BMY). Before poring over the specifics, here's what immunotherapy means: it's a type of cancer treatment that uses the body's immune system to put up a fight against cancer cells.
You may be surprised to hear this, but a large amount of short interest in a stock could actually be a buy signal.What is short selling a stock? It's selling a stock that you don't own with the intention of buying it back at a lower price in the future, usually using options. And short interest is the number of shares that are sold short that haven't been bought back yet. It is usually expressed as a ratio of shares that are short to the total number of outstanding shares.The short interest can also be expressed as "Days to Cover." This is the number of short shares divided by the average daily trading volume. In other words, it is the number of days that it would take for all the short shares to be bought back.InvestorPlace - Stock Market News, Stock Advice & Trading TipsI should note, this number should be considered understated, because it assumes purchasing 100% of the volume. This would be impossible in normal markets. It would be more realistic to assume that short sellers could only buy about 10%-15% of the average daily volume with adversely affecting the price. * 7 Safe Stocks to Buy for Anxious Investors You should pay attention to this because really high short-interest could be a bullish signal. This is because these shares need to be bought back. These short-sellers will all eventually become buyers! Trupanion (TRUP)Trupanion (NASDAQ:TRUP) provides medical insurance for cats and dogs. It has a subscription business and also offers insurance to companies that can provide it as a benefit to their employees.There are about 11.2 million shares currently short. This is 38% of the outstanding float. The average daily volume recently is about 145,000. That means the days to cover would be about 77. And remember, that assumes buying 100% of the volume.It would be more realistic to assume that one could only trade about 10% of the volume without adversely affecting the price. That means it could take years for the shorts to cover all of their positions!Wall Street seems to disagree with the shorts. Six firms follow it and the all have buy ratings on it. The average price target is $40. Accelerate Diagnostics (AXDX)Accelerate Diagnostics (NASDAQ:AXDX) engages in developing and selling instruments that are used to fight infectious pathogens.There are 14.1 million shares currently short in this company. That is 52% of the float. That means that there are guaranteed buyers for about half of the company's stock! Assuming that they buy 10% of the average daily volume, it would take about two years to cover it. * 7 Stocks to Buy for Over 20% Upside Potential All four of the analysts who cover this have a buy rating on it according to Yahoo Finance. OptiNose (OPTN)OptiNose (NASDAQ:OPTN) develops and sells products that are for the treatment of ear, nose, throat and allergy illnesses.The short-interest is 7.9 million, or about 49% of the float. Over the past year, the price of the stock has fallen from $30 to current levels around $9.Wall Street doesn't feel as bad about this company's prospects as the short sellers do. It likes this stock. All four analysts that follow it have it rated as a buy and the average target price is $25. That is about three times higher then where it is currently trading. Energy Recovery (ERII)Energy Recovery (NASDAQ:ERII) develops and sells products that are for industrial fluid flow application. Their customers include oil and gas companies.5.5 million shares are currently short. That is about 14% of the float. It isn't as much as the other companies, but it is still pretty high. It only trades about 112,000 on a typical day, so that would give a days to cover number of about 50. Using our estimate of being able to only acquire about 10%-15% of the volume that trades with adversely affecting the price, it would take over a year to cover. * 7 High-Yield REITs to Buy (Even When the Market Tanks) There are six buys on this company. The average target price is about $16, which is about 60% above current prices. Seres Therapeutics (MCRB)Seres Therapeutics (NASDAQ:MCRB) creates medicines "using live bacteria to treat diseases that result from functional deficiencies in the microbiome."The share price fell dramatically over the past month. The current short interest is 5.3 million of the float. That is about 25%. With an average daily volume of about 111,000, the days to cover is 48.This company is followed by nine Wall Street firms. Seven have it rated as a buy and the other two have it as a hold. The average target price is $11 and it is currently trading below $5. Theravance Biopharma (TBPH)Theravance Biopharma (NASDAQ:TBPH) is a biopharmaceutical company. It focuses and the research, development and commercialization of small molecule medicines.The short-interest ratio here is "only" 15%, or 6.3 million shares. The stock only trades about 154,000 shares on a typical day, so that is 41 days to cover.Remember, it is safe to assume that they can buy about 10% of the volume without adversely affecting the price. * 6 Chinese Stocks That Could Pop On a Trade Deal Seven firms follow this company. Four of them have it rated a buy and three have it as a sell. The average target price is just over $38 per share.As of this writing, Mark Putrino did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Safe Stocks to Buy for Anxious Investors * 4 Tech Stocks Looking Vulnerable * Should You Buy, Sell, Or Hold These 7 Hot IPO Stocks? Compare Brokers The post You Can Get Buy Signals From Short Selling appeared first on InvestorPlace.
Merck (MRK) signs a definitive agreement to buy small private biotech, Peloton Therapeutics for $1.05 billion in cash to boost its oncology pipeline.
The market may have popped on Tuesday, but it wasn't a terribly impressive move. The S&P 500's 0.85% gain still left it below some key technical lines, and the volume behind the gain was tepid.Source: Allan Ajifo via Wikimedia (Modified)Array Biopharma (NASDAQ:ARRY) was the big winner, gaining 23% following news that its colon cancer regimen met its endgoals in a late-stage trial. Among the more familiar, large and market-moving names though, the 2.5% gain Advanced Micro Devices (NASDAQ:AMD) logged was less thrilling though more noteworthy. The partial alleviation of trade tensions, particularly surrounding tech, released the hold that had stymied most of these names on Monday.At the other end of the spectrum, retailer Kohl's (NYSE:KSS) was crushed, losing more than 12% of its value on the heels of lousy Q1 print that forced the company to dial back its full-year profit forecast … weakness that wasn't necessarily mirrored by other retailers.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Small-Cap Stocks That Look Like Bargains None of those names are compelling trade prospects as we head into the midpoint of the week, however. Rather, it's the stock charts of TJX Companies (NYSE:TJX), Lamb Weston Holdings (NYSE:LW) and Oracle Corporation (NYSE:ORCL) that are worth the closest look. Here's that look. Oracle Corporation (ORCL)Oracle shares have dished out an impressive runup since late last year, and for the most part have sidestepped the recent market turbulence.Take a closer look at both stock charts, though, and it's clear that momentum is slowing. Indeed, it has stopped and it is teetering on a reversal back into a downtrend. One or two more rough days could put shares into a more pronounced selloff. Click to Enlarge * The most important line to watch now is the one that tags all the key lows going back early February. It's plotted in yellow on the daily chart. It's at $53.59 right now. * Although that floor is still intact, ORCL has already pulled below the purple 50-day moving average line a couple of different times. * Zooming out to the weekly chart of Oracle, all the key bearish clues are lining up. The RSI line only had to kiss the 70 level last month before starting to unwind, and we could see a bearish MACD cross before the end of the week. That latter event could spur some programmed selling. TJX Companies (TJX)In the middle of yesterday's trading session, TJX Companies shares looked like they were in real trouble. Already trending lower from a late-April peak, fresh pressure was being put on the white 200-day moving average line. Despite the earnings beat and raised outlook, traders saw matters through a bearish lens … right up until they didn't.By the end of the day, TJX shares were back in the black, having pushed up and off of the critical 200-day line. The big intraday swing backed by a clear volume surge suggesting a major turning of the tide. There's just one more hurdle for the bulls to clear, though it's a huge one. * 7 Safe Stocks to Buy for Anxious Investors Click to Enlarge * The big hurdle in question is actually the combination of the blue 20-day moving average line at $53.88 as well as the purple 50-day moving average line at $53.57. * The scope of the swing itself is telling, indicating a sweeping change of heart, prompted by news. Such reversals tend to go somewhere. * Almost just as likely, though, is a breakdown. Should the bears decide to retest the 200-day line at $51.49 (and the gray 100-day moving average line right below it at $51.18) and it fails to hold as a floor, the bearish momentum in place since late April could pile-drive the stock following a failed reversal. Lamb Weston Holdings (LW)Finally, when we last looked at Lamb Weston Holdings a month ago, we cautioned that while it had not yet broken below a major support line, the undertow was alarmingly bearish. The selling volume was picking up the pace as well.It turned out to be a worthy worry, though only for a few days. While LW stock edged its way back higher, it met a familiar technical ceiling to end up breaking under any of what could have been technical floors. A new one has been made in the meantime, but it's not great, and also starting to crumble. Click to Enlarge * The newest technical floor is right around $65.17, plotted in blue on the daily chart. That's more or less where Lamb Weston has found support since the beginning of the month. * Although there's a floor in play now, both of the more meaningful support lines plotted in red and yellow on both stock charts have been snapped. * It's easy to overlook, but the purple 50-day moving average line is now below the white 200-day moving average … a so-called "death cross" that suggests more selling is ahead. * It's only readily evident on the weekly chart, but with the break under the yellow "neckline," Lamb Weston appears to have just completed a bearish head-and-shoulders setup.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Safe Stocks to Buy for Anxious Investors * 4 Tech Stocks Looking Vulnerable * Should You Buy, Sell, Or Hold These 7 Hot IPO Stocks? Compare Brokers The post 3 Big Stock Charts for Wednesday: Oracle, Lamb Weston Holdings and TJX Companies appeared first on InvestorPlace.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 21) Array Biopharma Inc (NASDAQ: ARRY ) (announced positive ...
Ted Samuels paid $236,440 for 5,000 shares last week. It’s the first open-market purchase of Bristol-Myers stock by an insider in a year.
Earnings, trial results, and acquisition activity were contributing factors to today's move higher for the stock market.
Shares jumped in Tuesday's session after favorable clinical trial results paved the way for potentially near-term marketing approval.